Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease - a health insurance claims data analysis

Standard

Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease - a health insurance claims data analysis. / Kaschwich, Mark; Peters, Frederik; Hischke, Sandra; Rieß, Henrik C; Gansel, Max; Marschall, Ursula; L'Hoest, Helmut; Heidemann, Franziska; Debus, E Sebastian; Acar, Laura; Kreutzburg, Thea; Behrendt, Christian-Alexander.

In: VASA, Vol. 49, No. 6, 10.2020, p. 493-499.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{a4e28ce4f5404ac0b6f9dd350b8d9776,
title = "Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease - a health insurance claims data analysis",
abstract = "Background: Cancer as a concomitant condition in symptomatic peripheral arterial disease (PAD) patients could have an impact on further therapy and the long-term prognosis of these patients. Aim of this study was to investigate whether there is an increased incidence of cancer in PAD patients and to quantify the corresponding effect size. Materials and methods: Between January 1st, 2008 and December 31st, 2017, we analysed health insurance claims data from Germany's second-largest insurance fund, BARMER. Symptomatic PAD patients suffering from intermittent claudication (IC) or chronic limb-threatening ischaemia (CLTI) were stratified by gender at index treatment. PAD patients were then followed until an incident cancer diagnosis was recorded. To adjust for age and gender, standardized incidence ratios (SIR) were computed using the 2012 German standard population as reference. Results: 96,528 PAD patients (47% female, 44% IC, mean age 72 years) were included in the current study. When compared to the overall population, female and male PAD patients have a significantly increased risk of incident cancer of the lung (SIR 3.5 vs. 2.6), bladder (SIR 3.2 vs. 4.0), pancreas (SIR 1.4 vs. 1.6), and colon (SIR 1.3 vs. 1.3). During ten years of follow-up, some 7% of males and 4% of females developed lung cancer. For bladder, colon and pancreas cancer, the cumulative hazards were 1% vs. 3.2%, 2.2% vs. 2.8%, and 0.7% vs. 0.9%, respectively. Conclusions: Patients suffering from symptomatic PAD face a markedly higher risk for incident cancer in the long-term follow-up. The cancer risk increased continuously for certain types and PAD was strongly associated with cancer of the lung, bladder, pancreas, and colon. Taking these results into account, PAD patients could benefit from secondary and tertiary screening. These results also emphasize the impact of common risk factors such as tobacco smoke as target for health prevention.",
keywords = "Aged, Data Analysis, Female, Humans, Incidence, Insurance, Health, Male, Neoplasms/diagnosis, Peripheral Arterial Disease/diagnosis, Retrospective Studies, Risk Factors",
author = "Mark Kaschwich and Frederik Peters and Sandra Hischke and Rie{\ss}, {Henrik C} and Max Gansel and Ursula Marschall and Helmut L'Hoest and Franziska Heidemann and Debus, {E Sebastian} and Laura Acar and Thea Kreutzburg and Christian-Alexander Behrendt",
year = "2020",
month = oct,
doi = "10.1024/0301-1526/a000901",
language = "English",
volume = "49",
pages = "493--499",
journal = "VASA",
issn = "0301-1526",
publisher = "Hans Huber",
number = "6",

}

RIS

TY - JOUR

T1 - Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease - a health insurance claims data analysis

AU - Kaschwich, Mark

AU - Peters, Frederik

AU - Hischke, Sandra

AU - Rieß, Henrik C

AU - Gansel, Max

AU - Marschall, Ursula

AU - L'Hoest, Helmut

AU - Heidemann, Franziska

AU - Debus, E Sebastian

AU - Acar, Laura

AU - Kreutzburg, Thea

AU - Behrendt, Christian-Alexander

PY - 2020/10

Y1 - 2020/10

N2 - Background: Cancer as a concomitant condition in symptomatic peripheral arterial disease (PAD) patients could have an impact on further therapy and the long-term prognosis of these patients. Aim of this study was to investigate whether there is an increased incidence of cancer in PAD patients and to quantify the corresponding effect size. Materials and methods: Between January 1st, 2008 and December 31st, 2017, we analysed health insurance claims data from Germany's second-largest insurance fund, BARMER. Symptomatic PAD patients suffering from intermittent claudication (IC) or chronic limb-threatening ischaemia (CLTI) were stratified by gender at index treatment. PAD patients were then followed until an incident cancer diagnosis was recorded. To adjust for age and gender, standardized incidence ratios (SIR) were computed using the 2012 German standard population as reference. Results: 96,528 PAD patients (47% female, 44% IC, mean age 72 years) were included in the current study. When compared to the overall population, female and male PAD patients have a significantly increased risk of incident cancer of the lung (SIR 3.5 vs. 2.6), bladder (SIR 3.2 vs. 4.0), pancreas (SIR 1.4 vs. 1.6), and colon (SIR 1.3 vs. 1.3). During ten years of follow-up, some 7% of males and 4% of females developed lung cancer. For bladder, colon and pancreas cancer, the cumulative hazards were 1% vs. 3.2%, 2.2% vs. 2.8%, and 0.7% vs. 0.9%, respectively. Conclusions: Patients suffering from symptomatic PAD face a markedly higher risk for incident cancer in the long-term follow-up. The cancer risk increased continuously for certain types and PAD was strongly associated with cancer of the lung, bladder, pancreas, and colon. Taking these results into account, PAD patients could benefit from secondary and tertiary screening. These results also emphasize the impact of common risk factors such as tobacco smoke as target for health prevention.

AB - Background: Cancer as a concomitant condition in symptomatic peripheral arterial disease (PAD) patients could have an impact on further therapy and the long-term prognosis of these patients. Aim of this study was to investigate whether there is an increased incidence of cancer in PAD patients and to quantify the corresponding effect size. Materials and methods: Between January 1st, 2008 and December 31st, 2017, we analysed health insurance claims data from Germany's second-largest insurance fund, BARMER. Symptomatic PAD patients suffering from intermittent claudication (IC) or chronic limb-threatening ischaemia (CLTI) were stratified by gender at index treatment. PAD patients were then followed until an incident cancer diagnosis was recorded. To adjust for age and gender, standardized incidence ratios (SIR) were computed using the 2012 German standard population as reference. Results: 96,528 PAD patients (47% female, 44% IC, mean age 72 years) were included in the current study. When compared to the overall population, female and male PAD patients have a significantly increased risk of incident cancer of the lung (SIR 3.5 vs. 2.6), bladder (SIR 3.2 vs. 4.0), pancreas (SIR 1.4 vs. 1.6), and colon (SIR 1.3 vs. 1.3). During ten years of follow-up, some 7% of males and 4% of females developed lung cancer. For bladder, colon and pancreas cancer, the cumulative hazards were 1% vs. 3.2%, 2.2% vs. 2.8%, and 0.7% vs. 0.9%, respectively. Conclusions: Patients suffering from symptomatic PAD face a markedly higher risk for incident cancer in the long-term follow-up. The cancer risk increased continuously for certain types and PAD was strongly associated with cancer of the lung, bladder, pancreas, and colon. Taking these results into account, PAD patients could benefit from secondary and tertiary screening. These results also emphasize the impact of common risk factors such as tobacco smoke as target for health prevention.

KW - Aged

KW - Data Analysis

KW - Female

KW - Humans

KW - Incidence

KW - Insurance, Health

KW - Male

KW - Neoplasms/diagnosis

KW - Peripheral Arterial Disease/diagnosis

KW - Retrospective Studies

KW - Risk Factors

U2 - 10.1024/0301-1526/a000901

DO - 10.1024/0301-1526/a000901

M3 - SCORING: Journal article

C2 - 32807045

VL - 49

SP - 493

EP - 499

JO - VASA

JF - VASA

SN - 0301-1526

IS - 6

ER -